iavi researches and develops vaccine candidates conducts policy analyses serves as an advocate for the hiv prevention field and engages communities in the trial process and aids vaccine education the organization takes a comprehensive approach to hiv and aids that supports existing hiv prevention and treatment programs while emphasizing the need for new aids prevention tools it also works to ensure that future vaccines will be accessible to all who need them in 1994 the rockefeller foundation convened an international meeting of aids researchers vaccinologists public health officials and representatives from philanthropic organizations in bellagio italy to evaluate the challenges facing hiv aids vaccine development and identify ways to jump start research iavi s scientific team drawn largely from private industry researches and develops aids vaccine candidates and engages in clinical trials and research through partnerships with more than 100 academic biotechnology pharmaceutical and governmental institutions in september 2009 a global group of researchers led by iavi published a study in the journal science identifying pg9 and pg16 two highly powerful broadly neutralizing antibodies against a wide variety of hiv variants the site on the virus to which pg9 and pg16 attach revealed a vulnerability on hiv pg9 and pg16